Cancer Prevention and Control CIRB Meeting Agenda
March 24, 2022

I. Continuing Review

A171601, A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer (Protocol Version Date 05/29/20)

II. Continuing Review

A221805, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Protocol Version Date 01/12/22)

III. Continuing Review

NRG-CC009, Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (Protocol Version Date 01/20/21)

IV. Continuing Review

S1600, A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMmune) (Protocol Version Date 11/09/21)

V. New Study - Initial Review

S2108CD, A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy (Protocol Version Date 02/02/22)
VI. New Study - Initial Review

**UWI20-04-01**, A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer (Protocol Version Date 02/11/22)

VII. Amendment

**URCC-19075**, Multi-center Randomized Controlled Phase II Trial to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN) (Protocol Version Date 02/10/22)